Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge

BackgroundIt has been reported that immunotherapy with programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab or nivolumab) can induce multiple eruptive keratoacanthomas (KAs), representing an immune-related cutaneous adverse event (ircAE).MethodsThis case report describes a 63-year-old fe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying-Jie Su, Zheng Wu, Yan-Li Hou, Meng-Xia Yan, Xiu-Mei Ma, Hou-Wen Lin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Pharmacology
Subjects:	immune checkpoint inhibitors programmed cell death protein 1 immune-related adverse event immune-related cutaneous adverse event eruptive keratoacanthomas
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1619450/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
by: E. A. Degtiareva, et al.
Published: (2022-11-01)

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Construction of predictive model for programmed death-1 inhibitor-related endocrine adverse events
by: Jiaying SHI, et al.
Published: (2025-08-01)

Analysis of the clinical characteristics of immune checkpoint inhibitor-related hypophysitis
by: Zhixiao WANG, et al.
Published: (2025-08-01)

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report
by: Nidhi Kuchimanchi, et al.
Published: (2025-07-01)

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
by: Nora Möhn, et al.
Published: (2025-12-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
by: Clémence M. C. Huigen, et al.
Published: (2025-08-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

Adrenal insufficiency induced by immune checkpoint inhibitors anticancer therapy
by: Paulina Ramaneckaite, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology
by: Eri Yamabe, et al.
Published: (2025-10-01)

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01)

Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem
by: A. D. Koltakova, et al.
Published: (2023-10-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Corrigendum: Case report: Multi-organ injuries induced by tislelizumab
by: Man Yuan, et al.
Published: (2025-06-01)

Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
by: Panagiotis T. Diamantopoulos, et al.
Published: (2025-04-01)

Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
by: Yusuke Inoue, MD, PhD, et al.
Published: (2025-08-01)

Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency
by: Xiao Huang, et al.
Published: (2025-08-01)

Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient
by: Jianhao Ke, et al.
Published: (2025-06-01)

Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report
by: Zaid Khamis, et al.
Published: (2025-08-01)

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes
by: Hui Yang, et al.
Published: (2025-05-01)

Analysis of risk factors related to thyroid function abnormality caused by programmed death-1 inhibitors
by: Lihong WANG, et al.
Published: (2025-08-01)

ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies
by: Jixuan Zheng, et al.
Published: (2025-04-01)

Challenges in subtyping disease entities of thyroid dysfunction following combined immune checkpoint inhibitor therapy: a case report
by: Marco Juul Thomsen, et al.
Published: (2025-07-01)

Causal relationships between immune-related adverse events, immune cell characteristics, and plasma metabolites: insights from Mendelian randomization study
by: Zhiyuan Shi, et al.
Published: (2025-07-01)

Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study
by: Yujuan Wu, et al.
Published: (2025-07-01)

Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements
by: L. D. Khidirova, et al.
Published: (2024-06-01)

Pathogenesis, diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
by: Yi SUN, et al.
Published: (2025-04-01)

Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis
by: Lauris Annatha Mariam Auch, et al.
Published: (2025-08-01)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
by: Elisa Gozzi, et al.
Published: (2020-05-01)

Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors
by: Yu Akazawa, et al.
Published: (2025-07-01)

Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis
by: Magdalena Röckel, et al.
Published: (2025-08-01)

Clinical management and analysis of immune-related adverse events in neoadjuvant immunotherapy for locally advanced rectal cancer
by: AN Yang, WANG Chentong, QIU Xiaoyuan, ZHOU Jiaolin, LIN Guole
Published: (2025-07-01)

Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
by: Anqi Lin, et al.
Published: (2025-06-01)

Effect of the combination of remifentanil and neuromuscular blockers in pediatric endotracheal intubation: a prospective, double-blinded, randomized clinical trial
by: Lanxin Qiao, et al.
Published: (2025-08-01)

Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
by: Omar Elghawy, MD, et al.
Published: (2025-09-01)

Cerebral small vessel disease as a possibly immune-related adverse event of immunotherapy in lung cancer patients: a retrospective study
by: Na Wu, et al.
Published: (2025-08-01)

Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database
by: Guojing Yao, et al.
Published: (2025-08-01)

A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic
by: Florence van Hunsel, et al.
Published: (2025-08-01)

Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective
by: Maria Maddalena Lino, et al.
Published: (2025-04-01)